Tag Archives: Federal Circuit

Ariosa Diagnostics v. Sequenom: Another One Bites The Dust

Posted on November 11, 2013 by Warren Woessner

In Ariosa Diagnostics, Inc. v. Sequenom, Inc., 2013 U.S. Dist. LEXUS 156554, the U.S. District Ct. for N.D. Cal., granted summary judgment to Ariosa that the claims of U.S. Patent No. 6,258,540 were invalid as directed to patent-ineligible natural phenomena … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 3 Comments

Sanofi-Aventis v. Pfizer – Possession and Appreciation Trump Structure

Posted on November 6, 2013 by Warren Woessner

On Tuesday, the Fed. Cir. affirmed a finding by the Board that Pfizer was entitled to an earlier priority date for a claim to  cDNA encoding the IL-13 receptor protein (Sanofi-Aventis v. Pfizer, Inc., App. No. 2012-1345 (Fed. Cir. November … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , | Leave a comment

Synthes v. Spinal Kinetics – When “Structure” is Not Enough

Posted on November 4, 2013 by Warren Woessner

  A guest post from Domenico Ippolito of Schwegman Lundberg & Woessner, P.A. Synthes USA, LLC v. Spinal Kinetics, Inc., 2013-1047, -1059, (Fed.Cir. Oct 29, 2013) concerns a medical device patent, but addresses issues common to all patents.  The primary … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , | Leave a comment

Novozymes Loses “Possession” Of Its Enzyme

Posted on November 1, 2013 by Warren Woessner

I am not sure how I missed this decision, which came down on July 22nd, but it offers a rather scary hi-def picture as to where the written description requirement of s. 112 has been and where it is headed. … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , | 1 Comment